Results 91 to 100 of about 519,893 (158)

mRNA-vacciner mot SARS-CoV-2 (Pfizer BionTech BNT162b och mRNA-1273 Moderna) -analys av säkerhet och effektivitet

open access: yes, 2022
Introduction: The coronavirus is an RNA virus with a lipid envelope. The initially known coronaviruses are (MERS-CoV and SARS-CoV) which caused fatal endemics in 2002 and 2012.
Mohamedhusein, Doaa Rashad
core   +3 more sources

Effectiveness and evolution of anti-SARS-CoV-2 spike protein titers after three doses of COVID-19 vaccination in people with HIV

open access: yesJournal of Microbiology, Immunology and Infection
Background: Real-world vaccine effectiveness following the third dose of vaccination against SARS-CoV-2 remains less investigated among people with HIV (PWH).
Wang-Da Liu   +26 more
doaj   +1 more source

Delayed skin reaction after mRNA-1273 vaccine against SARS-CoV-2: a rare clinical reaction

open access: yes, 2021
BACKGROUND: The coronavirus disease 2019 (COVID-19) is associated with a wide clinical spectrum of skin manifestations, including urticarial, vesicular, vasculitic and chilblain-like lesions.
Rezazadeh, Amir   +65 more
core   +1 more source

Anti-SARS-CoV-2 antibody dynamics after primary vaccination with two-dose inactivated whole-virus vaccine, heterologous mRNA-1273 vaccine booster, and Omicron breakthrough infection in Indonesian health care workers

open access: yesBMC Infectious Diseases
Background Data on the dynamics and persistence of humoral immunity against SARS-CoV-2 after primary vaccination with two-dose inactivated vaccine (CoronaVac) are limited.
Suwarti Suwarti   +23 more
doaj   +1 more source

Relationship between differentially expressed mRNA and mRNA-protein correlations in a xenograft model system [PDF]

open access: yes, 2015
This work was supported by Medical Research Scotland (FRG353 to VAS), the FP7- Directorate-General for Research and Innovation of the European Commission (EU HEALTHF4-2012-305033 to Coordinating Action Systems Medicine to DJH); the Chief Scientist Office
Smith, V. Anne   +7 more
core   +1 more source

Abstracts

open access: yesMolecular Oncology, Volume 20, Issue S1, Page 1-692, August 2026.
Abstracts submitted to the ‘EACR 2026 Congress: Innovative Cancer Science’, from 08–11 June 2026 and accepted by the Congress Organising Committee are published in this Supplement of Molecular Oncology, an affiliated journal of the European Association for Cancer Research (EACR).
wiley   +1 more source

Moderna (mRNA Vaccine) for COVID-19: A Leap in Vaccine World

open access: yesPharmaceutical and Biomedical Research, 2022
In December 2019, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) appeared and spread worldwide, triggering a pandemic of respiratory illness. So, there was an urgent need for vaccines worldwide.
Anita Rani Bhatia   +4 more
doaj  

Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era

open access: yesVaccines
Background/Objectives: COVID-19 continues to challenge public health due to emerging variants. To mitigate this, the Korea Disease Control and Prevention Agency (KDCA) recommends annual COVID-19 vaccination, but uptake remains suboptimal.
Jaehee Jung   +9 more
doaj   +1 more source

Phase 1/2 randomized, observer-blind clinical trial of a first-generation, mRNA-based vaccine against seasonal influenza and COVID-19 in healthy adults

open access: yesHuman Vaccines & Immunotherapeutics
A multicomponent vaccine against seasonal influenza and COVID-19 could reduce disease burden in adults by providing simultaneous protection in a single-dose regimen.
Amanda K. Rudman Spergel   +22 more
doaj   +1 more source

Safety profile following mRNA-1273 COVID-19 primary vaccination in healthy adults in Indonesia. [PDF]

open access: yesGlob Epidemiol
Medise BE   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy